Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.
BACKGROUND
A 63-year-old woman with chronic myeloid leukemia (CML) received treatment with interferon (IFN)-α for 6 years. After achieving a complete cytogenetic response that was repetitively documented, IFN-α treatment was stopped. Despite maintenance of a complete cytogenetic response, a progressive rise of the BCR-ABL1 transcript was detected and loss of major molecular response occurred about 2 years after stopping IFN-α therapy. Disease remained at molecular level.


METHODS
Peripheral blood quantitative real-time PCR every 3 months and periodical bone marrow aspirate were performed to monitor disease.


METHODS
Chronic-phase, Philadelphia-positive CML that was still detectable after complete cytogenic response 2 years after cessation of IFN-α therapy.


RESULTS
The patient was treated with a target immune approach receiving a therapeutic vaccine that consisted of an immunogenic 25-mer b2a2 breakpoint-derived peptide (CMLb2a2-25) with binding properties for several HLA-DR molecules. After nine boosts of vaccine the patient developed an adequate b2a2-25 peptide-specific CD4(+) T-cell response and BCR-ABL1 transcript started to decline in peripheral blood. No hematological or extrahematological effects were documented during therapy. At the last evaluation, 39 months since vaccinations commenced, the patient is in complete molecular response with an undetectable level of BCR-ABL1 transcript both in peripheral blood and in bone marrow and she continues to receive boosts of vaccine every 3 months as the only treatment.
Bocchia
Monica
M
Hematology and Transplants, University of Siena and AOUS, Viale Bracci 16, 53100 Siena, Italy. bocchia@unisi.it
Defina
Marzia
M
Aprile
Lara
L
Ippoliti
Micaela
M
Crupi
Rosaria
R
Rondoni
Michela
M
Gozzetti
Alessandro
A
Lauria
Francesco
F
D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000097:blood*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D014611:Vaccination
D019496:Cancer Vaccines; D016898:Interferon-alpha; D016044:Fusion Proteins, bcr-abl
J Clin Oncol. 2010 Mar 10;28(8):1429-35
20142590
Nat Rev Clin Oncol. 2009 Sep;6(9):535-43
19652654
Lancet. 2007 Jul 28;370(9584):342-50
17662883
Blood. 2009 Oct 15;114(16):3376-81
19661271
J Clin Oncol. 2008 Jul 10;26(20):3358-63
18519952
Cancer. 2009 Sep 1;115(17):3924-34
19536894
Blood. 2008 Feb 15;111(4):1774-80
18055868
Blood. 2001 Nov 15;98(10):3074-81
11698293
Blood. 2007 Jan 1;109(1):58-60
16973963
Leukemia. 2009 Jun;23(6):1054-61
19282833
Leukemia. 2007 Nov;21(11):2287-95
17637811
Ann Hematol. 2002;81 Suppl 2:S45-6
12611074
N Engl J Med. 2006 Dec 7;355(23):2408-17
17151364
Lancet. 2005 Feb 19-25;365(9460):657-62
15721470
Leukemia. 2008 Jan;22(1):96-102
17943168